- Country wide surveillance reveals prevalent artemisinin partial resistance mutations with 1
- 2 evidence for multiple origins and expansion of high level sulfadoxine-pyrimethamine
- 3 resistance mutations in northwest Tanzania.
- 4
- Jonathan J. Juliano¹⁺, David J. Giesbrecht²⁺, Alfred Simkin², Abebe A. Fola², Beatus M. 5
- Lyimo^{3,4}, Dativa Pereus³, Catherine Bakari³, Rashid A. Madebe³, Misago D. Seth³, Celine I. 6
- Mandara³, Zachary R. Popkin-Hall¹, Ramadhan Moshi³, Ruth B. Mbwambo³, Karamoko Niaré², 7
- Bronwyn MacInnis^{5,6}, Filbert Francis², Daniel Mbwambo⁷, Issa Garimo⁷, Frank Chacky⁷, 8
- Sijenunu Aaron⁷, Abdallah Lusasi⁷, Fabrizio Molteni⁸, Ritha J. A. Njau⁹, Samwel Lazaro⁷, Ally Mohamed⁷, Jeffrey A. Bailey^{2,*}, Deus S. Ishengoma^{3,5,10*#} 9
- 10
- 11
- 12
- ¹University of North Carolina, Chapel Hill, NC, USA 13
- ²Brown University, Providence, RI, USA 14
- ³National Institute for Medical Research, Dar es Salaam, Tanzania. 15
- ⁴Nelson Mandela African Institute of Science and Technology, Arusha, Tanzania 16
- ⁵Harvard T.H Chan School of Public Health, Boston, MA, USA 17
- 18 ⁶Broad Institute, Boston, MA, USA.
- 19 ⁷National Malaria Control Programme, Dodoma, Tanzania
- ⁸Swiss Tropical Public Health Institute, Dar es Salaam, Tanzania 20
- ⁹Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania 21
- ¹⁰Faculty of Pharmaceutical Sciences, Monash University, Melbourne, Australia 22
- 23
- 24 +: co-first author
- *: co-senior authors 25
- 26
- 27 #Corresponding author: deusishe@yahoo.com
- 28

It is made available under a CC-BY-NC-ND 4.0 International license .

29 Abstract

30 **Background:** Emergence of artemisinin partial resistance (ART-R) in *Plasmodium falciparum* is

a growing threat to the efficacy of artemisinin combination therapies (ACT) and the efforts for

malaria elimination. The emergence of *Plasmodium falciparum* Kelch13 (K13) R561H in

33 Rwanda raised concern about the impact in neighboring Tanzania. In addition, regional concern

over resistance affecting sulfadoxine-pyrimethamine (SP), which is used for chemoprevention

35 strategies, is high.

36 **Methods**: To enhance longitudinal monitoring, the Molecular Surveillance of Malaria in

Tanzania (MSMT) project was launched in 2020 with the goal of assessing and mapping

38 antimalarial resistance. Community and clinic samples were assessed for resistance

39 polymorphisms using a molecular inversion probe platform.

40 **Findings:** Genotyping of 6,278 samples collected countrywide in 2021 revealed a focus of K13

41 561H mutants in northwestern Tanzania (Kagera) with prevalence of 7.7% (50/649). A small

42 number of 561H mutants (about 1%) were found as far as 800 km away in Tabora, Manyara, and

43 Njombe. Genomic analysis suggests some of these parasites are highly related to isolates

44 collected in Rwanda in 2015, supporting regional spread of 561H. However, a novel haplotype

45 was also observed, likely indicating a second origin in the region. Other validated resistance

46 polymorphisms (622I and 675V) were also identified. A focus of high sulfadoxine-

pyrimethamine drug resistance was also identified in Kagera with a prevalence of dihydrofolate
reductase 164L of 15% (80/526).

49 **Interpretation:** These findings demonstrate the K13 561H mutation is entrenched in the region

and that multiple origins of ART-R, similar as to what was seen in Southeast Asia, have

51 occurred. Mutations associated with high levels of SP resistance are increasing. These results

raise concerns about the long-term efficacy of artemisinin and chemoprevention antimalarials in

53 the region.

Funding: This study was funded by the Bill and Melinda Gates Foundation and the NationalInstitutes of Health.

It is made available under a CC-BY-NC-ND 4.0 International license .

57 **Research in Context**

58 Evidence before this study

59 We did a literature search via PubMed for research articles published from January 2014 to October 2023 using the search term "Africa" and "Artemisinin resistance" linked to "R561H" or 60 "A675V" or "R622I", returning 32 studies. The published literature shows the emergence and 61 establishment of these three validated *Plasmodium falciparum* kelch13 (K13) mutations 62 63 associated with artemisinin partial resistance (ART-R) in Africa. Large molecular studies of 64 675V in Uganda and 622I in Ethiopia have defined the regional spread of these mutations. However, limited data is available from recent studies about the spread and origins of the 561H 65 mutation in the Great Lakes region of East Africa. In particular, detailed studies of the regions of 66 67 Tanzania that border Rwanda have not been carried out since the mutation was detected in Rwanda. These data are needed for malaria control programs to define and implement strategies 68 for controlling the spread of ART-R in Africa, a potential global public health disaster and the 69

70 potential obstacle to the ongoing elimination strategies.

71 Added value of this study

72 This analysis reports the first large-scale analysis of antimalarial resistance in Tanzania, with a focus on the regions bordering Rwanda since the 561H mutation reached high frequency in the 73 area. Using 6.278 P. falciparum positive samples sequenced using molecular inversion probes 74 (MIPs), we show that the mutation has become frequent in the districts of Kagera bordering 75 Rwanda. Importantly, we provide evidence for the separate emergence of a different extended 76 77 haplotype around 561H in Tanzania. This is the first evidence that multiple independent emergences of the 561H ART-R have occurred in Africa, as was seen within the last two decades 78 79 in Southeast Asia.

80 Implications of all the available evidence

81 These findings highlight that, similar to 622I and 675V in other parts of Africa, we can expect

the 561H mutation to continue to spread in the region. In addition, it highlights that we need to

be watchful for new origins of mutations beyond the spread of existing resistant parasite

84 lineages. ART-R appears to now be well established in multiple areas in Eastern Africa.

85 Intensive control in these regions to prevent spread and monitoring for partner drug resistance

It is made available under a CC-BY-NC-ND 4.0 International license .

- 86 emergence in affected areas will be critical for preventing further reversal of malaria control
- efforts in the region and support progress to the elimination targets by 2023.

It is made available under a CC-BY-NC-ND 4.0 International license .

INTRODUCTION 89

Resistance to drugs used for treatment and prevention of malaria poses one of the greatest threats 90 91 to global control and is of grave concern in Africa where the vast majority of cases and deaths occur.¹ Historically, the emergence and spread of chloroquine and sulfadoxine-pyrimethamine 92 (SP) resistance resulted in the collapse of effective treatment of malaria with significant 93 increases in morbidity and mortality.² Antimalarial combination therapies, consisting of an 94 artemisinin derivative and a partner drug (artemisinin-based combination therapy - ACTs), are 95 currently the predominant therapeutic options for treating uncomplicated falciparum malaria. 96 Given gains in malaria control have already plateaued and are reversing in some countries, the 97 emergence of artemisinin partial resistance (ART-R) in Africa could be a global public health 98

disaster if partner drug resistance emerges in concert resulting in frank ACT failure.³ 99

100

Over a decade has passed since the emergence of ART-R in SouthEast Asian P. falciparum 101 populations, leading to decreased drug efficacy.⁴ Clinical ART-R was first demonstrated in the 102 late 2000s in studies conducted in Western Cambodia. The emergence of ART-R in Western 103 Cambodia set the stage for the eventual failure of ACTs, as resistance to the partner drugs also 104 emerged, indicated by increasing treatment failures, parasite clearance times and partner drug 105 IC50s over a very short timeframe.³ Early in the emergence of ACT resistance, many areas of 106 SEA experienced more than 50% failure in patients treated with ACTs due to the combined 107 effect of artemisinin and partner drug resistance.³ 108

109

Mutations in *Plasmodium falciparum* Kelch13 (K13) (PF3D7_1343700) are the key mediator of 110 ART-R. These mutations were originally identified through drug pressure experiments and 111 validated in the field and by genetic engineering studies.⁵ They are thought to alter ubiquitination 112 patterns and help parasites to resist accumulation of polyubiquitinated proteins.⁵ A number of 113 key mutations in K13 propeller domain are now validated markers of ART-R. Unfortunately, 114 validated K13 mutations have now been found extensively in Eastern Africa, particularly in the 115 Horn of Africa (R622I), Uganda (C469Y, A675V), Rwanda (R561H), and Tanzania (R561H).⁶⁻ 116 10

It is made available under a CC-BY-NC-ND 4.0 International license .

118

The regional emergence and spread of these mutations appears to be developing as the norm rather than the exception. In the Horn of Africa, the validated 622I mutation was first reported in 2014.¹¹ Since that time, these mutations have spread across Eritrea and Ethiopia.^{7,8} In Uganda, longitudinal molecular surveillance at 16 sites has painted a clear picture of spread within Uganda of the 469Y and 675V variants.⁶ It is important to note that all three of these mutations have been associated with prolonged parasite clearance, day 3 positivity by microscopy, increasing prevalence over time, and are in regions that now meet WHO criteria for ART-R.^{7,8}

126

127 The emergence and spread of the 561H mutation in the Great Lakes Region of East Africa is not yet as clear when compared to other mutations. Originally described in Rwanda in samples from 128 129 2014 and 2015, this mutation appears to have emerged within the country over the past decade.^{10,12} In 2015, 7.4% of samples collected in Masaka harbored the 561H mutation.¹⁰ By 130 2018, 561H prevalence had increased to 19.6% in Masaka and 22% in Rukara during a 131 therapeutic efficacy study.¹³ In this study, 50% of isolates with delayed clearance (day 3 positive 132 133 parasitemia) carried 561H. On this basis, Masaka met the WHO criteria for endemic ART-R as defined by >5% of patients carrying K13 resistance-confirmed mutation for which they had 134 persistent parasitemia by microscopy on day 3.¹⁴ Genome sequencing of isolates from 2015 also 135 confirmed a single haplotype of 561H in Rwanda that was not of Asian origin, suggesting de 136 *novo* mutation within Africa.¹⁰ 137

138

Importantly, K13 mutations should never be studied in isolation as it requires partner drug 139 140 resistance to lead to clinical failures of ACTs. Further, mutations to drugs no longer used for therapy, but that remain in use for chemoprevention (e.g. SP), are also important to characterize 141 142 for malaria control programs. Molecular surveillance of antimalarial resistance should therefore rely on platforms that can broadly detect different resistance mutations. Highly multiplex 143 amplicon deep sequencing is one approach that has shown promise. Another approach is 144 molecular inversion probes (MIPs), which have now been used extensively to characterize drug 145 resistance and population structure in parasites in Africa.^{8,9,15} The ability to create and combine 146

It is made available under a CC-BY-NC-ND 4.0 International license .

147 different highly multiplexed panels for antimalarial resistance mutations, copy number variation,

gene deletions and other genome wide polymorphisms to study complexity of infection, parasite

relatedness or population structure makes the MIP platform a highly flexible and cost-effective

150 means of conducting malaria molecular surveillance (MMS).

151

The Molecular Surveillance of Malaria in Tanzania (MSMT) project was developed to provide 152 nationwide longitudinal surveillance of parasite populations to understand key aspects of parasite 153 biology that may impact malaria control and interventions.¹⁶ The emergence of 561H is a prime 154 concern for Tanzania given its proximity to Rwanda and previous studies documenting isolated 155 cases across the country, with two cases in the Chato district and one on the Eastern coast.^{9,17} 156 157 Here we describe the initial assessment of 6,278 successfully genotyped samples collected across 158 7,782 malaria positive individuals in the first year of the project using high-throughput MIP 159 analysis. The goal was to assess the status of antimalarial resistance in Tanzania, with a focus on 160 the border with Rwanda, to understand the distribution of the 561H mutation, partner drug 161 resistance and resistance to chemoprevention drugs. This was further supported by whole genome sequencing of specific isolates to understand flanking haplotypes and gain insight into 162 the origins of 561H mutations in Tanzania. 163

It is made available under a CC-BY-NC-ND 4.0 International license .

164 MATERIALS AND METHODS

165 Study Design and Participants

We analyzed dried blood spot (DBS) samples from patients with a positive malaria rapid 166 diagnostic test drawn from cross-sectional surveys that involved 100 health facilities in 10 167 168 regions (n=7,148) and asymptomatic individuals in community studies (n=634) in three additional regions (Figure 1). Details of the study sites' selection and overall sampling have 169 been provided elsewhere.¹⁶ The three community surveys were conducted in regions of Tanzania 170 171 which were involved in previous studies undertaken by the National Institute for Medical Research (NIMR).^{9,18} Four regions (Kagera, Mara, Tabora, and Kigoma) were deemed high 172 priority areas for antimalarial resistance surveillance due to their proximity to Rwanda and to 173 174 their location in the Lake Zone of the country with higher transmission (Figure 1). Informed 175 consent was obtained for each patient and de-identified DBS samples were processed at NIMR in 176 Tanzania, Brown University, and University of North Carolina (USA) according to IRB 177 requirements of the Tanzanian Medical Research Coordinating Committee (MRCC) of NIMR.

178

179 Molecular Inversion Probe Analysis

180 DNA was extracted from the DBS using a Chelex-Tween protocol and MIP captures and sequencing were conducted as previously described.¹⁵ This study used a panel specific for drug 181 resistance polymorphism detection and a panel to look at genomic diversity.¹⁵ Approximately 182 two to three thousand samples were run together on each NextSeq 500 run, and sample libraries 183 184 lacking sufficient read depth were rebalanced and resequenced. For samples from the high priority regions (Figure 1), an additional MIP capture and high-depth sequencing was 185 conducted. Resulting data was analyzed using MIPtools software with freebayes variant 186 calling (https://github.com/bailey-lab/MIPTools).¹⁵ Controls for each MIP capture and 187 sequencing included DNA from 3D7 and 7G8 as well as no template and no probe controls. 188 Variant calling was conducted as previously described.¹⁵ We kept samples that had at least one 189 haplotype that mapped in the expected locations of the genome for any of our drug resistance 190 191 MIPs. Antimalarial resistance prevalence was calculated for all variants with a UMI count of 3 or greater and if heterozygous with the alternate allele having 1 UMI or greater using a Python 192

It is made available under a CC-BY-NC-ND 4.0 International license .

script and maps were created using the sf package. Analysis of haplotypes involves only samples

194 where complete genotypes across the involved loci are available. Inheritance by descent (IBD)

analysis of parasite relatedness among ART-R parasitemias was done as previously described.⁸

196

197 Whole Genome Sequencing

198 Whole genome sequencing of selective whole genome amplification (sWGA) products was attempted for 23 pure 561H, 5 mixed R561H, and 45 wildtype parasite infections based on MIP 199 200 genotyping. sWGA was performed in triplicate for each sample using a previously published protocol and pooled.¹⁹ The pooled sWGA product was sheared using a LE220R-plus Covaris 201 202 Sonicator and libraries prepared using dual indexing with the Kappa Hyper Prep Kit (Roche, Indianapolis, IN). Pooled libraries were sequenced on a NovaSeq6000 using 2 x 150 bp 203 chemistry at the University of North Carolina (UNC) High Throughput Sequencing Facility. We 204 205 also downloaded publicly available WGS data (n=25) from *P. falciparum* isolates collected in 2014/15 in Rwanda.¹⁰ 206

207

Whole genome sequencing data was analyzed using GATK4 following previously published 208 methods (https://github.com/Karaniare/Optimized GATK4 pipeline).²⁰ Briefly, reads were 209 210 mapped to the 3D7 reference genome using bwa mem, variants were called using GATK4 and SNPs and indels were filtered using variant quality score recalibration. SNPs and indels passing 211 filters were visualized in R 4.2.1 using the gt package. In order to detect patterns of selection 212 213 signals between Southeast Asian (SEA), Rwanda and Tanzania haplotypes, we did extendedhaplotype homozygosity (EHH) statistics focusing 561H drug resistance SNP using filtered 214 215 biallelic SNPs and with low missingness data from a VCF file. All associated EHH calculations were carried out using the R-package rehh (version 2.0.4). Rwanda and SEA data was 216 downloaded from Pf7K. 217

It is made available under a CC-BY-NC-ND 4.0 International license .

218 **RESULTS**

219 We successfully genotyped 6,278 of the 7,782 (80.7%) samples attempted (Figure 1B).

- 220 Sequencing across the K13 gene revealed three WHO validated ART-R mutations, 561H, 622I,
- and 675V. The 561H mutations were predominantly found in Kagera, the northwest most region
- bordering Rwanda and Uganda. (Figure 2A, Table 1). The overall prevalence in Kagera was
- 223 7.7% (50/649) and most of these mutant parasites were found in the west near the Rwandan
- border in the districts of Karagwe at 22.8% (31/136), Kyerwa at 14.4%% (17/118) and pfdhfr
- and pfdhps mutations were common in the area studied (Table 2). Notably, we identified Ngara,
- at 1.4% (2/144) (**Figure 2B**). Beyond Kagera, parasites with the 561H mutation were also
- detected at lower prevalence in three other regions, including Tabora at 0.5% (2/438), Manyara
- at 0.5% (1/179), and Njombe at 0.4% (1/279), as far as 800 km from the Rwanda border. The
- 229 K13 622I mutation was found in a single isolate from Njombe in Southwestern Tanzania (Table
- **1**). The 675V mutation was found in one isolate from Kagera and one isolate from Tabora. Other
- K13 propeller domain mutations not known to be associated with drug resistance were detected
- sporadically (**Table S1**). Outside the K13 propeller domain, we found several polymorphisms
- including 189T in 18.3% (397/2,168) of samples country-wide (**Table S1**). Other mutations have
- putatively been associated with partial artemisinin resistance outside of K13, including
- 235 *Plasmodium falciparum* ATPase 6 (ATPase6) and *P. falciparum* AP-2mu (AP2mu) (**Table S1**).
- The ATPase6 623E mutation was found in four Kagera isolates and seven Mara isolates (0.6%
- and 2.3%, respectively), and none of these isolates contained parasites with mutations at K13
- 238 561H. *P. falciparum* coronin was not genotyped.
- 239

Extended haplotypes around antimalarial genes have been used to study the origin and spread of 240 mutations.¹⁰ With positive directional selection of resistance by drug pressure, large genomic 241 sections are spread in the population, a selective sweep, which are eventually broken down 242 243 through recombination. We achieved sufficient depth and quality on 29 of 63 Tanzanian isolates from 2021 to assess the variation surrounding K13 and used publicly available WGS data from 244 the isolates collected in 2014/15 in Rwanda.¹⁰ We identify a shared haplotype between the older 245 Rwandan isolates and the contemporary Tanzanian isolates (n=4 from Tanzania; haplotype 246 247 RW/TZ1), suggesting cross-border spread resulting from a single origin event. However, a

It is made available under a CC-BY-NC-ND 4.0 International license .

second extended haplotype (n=5; TZ2) is also seen within the Tanzanian parasites (**Figure 3**).

249 RW/TZ1 and TZ2 differ at the closest flanking single nucleotide polymorphisms (within 1kb of

the 561H mutation). The TZ2 haplotype also does not appear to be of SEA origin (**Figure S1**).

251 Extended haplotype homozygosity analysis (EHH) shows extended haplotypes for RW/TZ1 and

TZ2 relative to wild type parasites, consistent with positive selection for both 561H haplotypes

253 (Figure 4). IBD analysis showed that 561H isolates from Kagera were closely related in multiple

small clusters (**Figure S2**). Of the more distant isolates, the two from Tabora were related to

Kagera isolates (IBD \geq 0.25), with the other two being more distant (**Figure S3**).

256

To investigate associations with mutations previously found to occur in drug resistant parasites 257 258 in Southeast Asia in combination with K13 mutations, we used the MIP panel genotypes and 259 quantified mutations occurring in the same isolates. None of P. falciparum chloroquine 260 resistance transporter (CRT) 326S, CRT 356T, P.multidrug resistance protein 2 (MDR2) 484I, 261 *Plasmodium falciparum* Protein phosphatase (PPH) 1157L, or putative phosphoinositide-binding 262 protein (PIB7) 1484F were associated with K13 561H mutant isolates. However, ferredoxin (FD) 193Y polymorphisms were found in 13 K13 561H mutant isolates in Kagera (Table S1). Known 263 partner drug resistance mutations were also assessed (**Table 1**). In Kagera, 39 samples (39/586) 264 265 had mutations at CRT 76T, and 31 of these isolates were from Ngara bordering Rwanda and Burundi (ASAQ is the most widely used ACT in Burundi). The multidrug resistance transporter 266 1 (MDR1) N86 allele associated with lumefantrine resistance was found in 99.9% of samples 267 (3828/3830). The MDR1 NFD haplotype (N86, 184F, D1246) was found in 52.6% of samples 268 (1420/2698).269

270

Markers for SP resistance were also genotyped, revealing high frequency of many mutations and the emergence of dihydrofolate reductase (DHFR) 164L in Kagera (**Table 1, Figure 2C**). The folate synthesis gene triple mutations DHFR 51I, 59R and 108N were found to be near fixation with the IRN haplotype at 92.5% (2,893/3,128). Notably, the DHFR 164L mutation was found at 15.2% (80/526) in Kagera region, accounting for 80% of the IRNL haplotypes found in the country (100/2,524 nationally) (**Figure 2C**). In the dihydropteroate synthase (DHPS) gene, two markers for elevated SP resistance were found to be above WHO guideline thresholds in some

- regions. DHPS 540E was found at 93.06% (3,485/3,745) in Tanzania with little geographic
- variation (**Table 1**), while DHPS 581G prevalence ranged from 0.4% (1/239) in Mtwara to
- 280 38.5% (25/65) in Tanga (**Figure 2D**).

It is made available under a CC-BY-NC-ND 4.0 International license .

282 **DISCUSSION**

Drug resistance in malaria parasites has emerged multiple times to every frontline antimalarial, 283 each time with severe consequences for affected populations.²¹ The emerging threat of ART-R in 284 Africa has the potential to be a global public health disaster. Thus, understanding the emergence 285 and spread of these mutations is critical in making plans to contain this threat. While it is clear 286 that K13 622I and 675V are spreading in the Horn of Africa and Uganda, respectively, the 287 288 pattern of origin and spread of the 561H mutation have not been fully defined. Here we 289 demonstrate that the mutation has risen to high frequencies in Kagera (7.7%), a region bordering 290 Rwanda, which had little evidence of resistance in a 2017 study that used MIPs to genotype samples from Kagera in a national schoolkids survey (data not published). This trend would be 291 292 consistent with outward spread from the Rwanda-Tanzania border, and also supports the idea that there has been and will continue to be regional spread of the mutation, especially given the 293 294 shared extended haplotype around some of the Tanzanian isolates and the older reported 295 Rwandan isolates. More concerning is the evidence of a potential unique origin of the 561H mutation in the region, suggesting that ART-R may follow patterns similar to those seen in 296 Southeast Asia with multiple independent origins of the same mutation.²² Haplotype analysis 297 suggests multiple origins, but does not prove the mechanism behind them.⁶ If multiple origins 298 299 occur, containment efforts are more difficult, due to the need to closely monitor for new 300 haplotypes and the spread of specific haplotypes, which may not become extensive without 301 partner drug resistance. However, the presence of multiple haplotypes may be due to gene conversion or recombination events adjacent to the mutation. 302

303

Several mutations in the K13 propeller domain that are now associated with delayed parasite 304 clearance are present in East Africa.^{6–8} The most concerning of these, 469Y, 561H, 622I and 305 675V, have shown clinical and in vitro validation of ART-R. Determining the exact origin of 306 these mutations with certainty is difficult due to the patchy nature of the surveillance data, but 307 308 one (561H) of the three appears to have originated on the Rwanda-Tanzania border. 561H was first detected in Rwanda in 2015 as part of therapeutic efficacy studies and later in DRC and 309 Tanzania.^{9,10} To date, genotyping efforts to describe the status of K13 mutations in Tanzania 310 311 have been limited and do not capture the risk posed by ART-R parasites across the country. The

It is made available under a CC-BY-NC-ND 4.0 International license .

312 high rate of human movement across the border with Rwanda, where people have close historical ties and One Stop Border Posts (OSPB) that routinely permit thousands of individuals and 313 314 hundreds of vehicles to cross daily, makes this a primary concern for malaria control in Tanzania.²³ While there have been sporadic reports of validated ART-R polymorphisms in the 315 316 past, systematic longitudinal surveillance of these mutations is necessary to identify areas at risk, as has been done in Uganda.^{6,9,17} The speed at which data is generated and reported to control 317 318 programs is critical. The MSMT project will provide these nationwide data for Tanzania given the identified threat shown here of 561H in Kagera, by allowing yearly sampling and in-country 319 sequencing and analysis of data as the project develops. 320

321

Partner drug resistance surveillance showed important patterns. An intriguing pattern of CRT 76T mutations was found to be clustered near the Burundi border. A possible explanation is that the use of ASAQ in Burundi is contributing to continued selection for chloroquine resistance and that these resistant parasites are being imported into Kagera. Given artemether-lumefantrine remains the first line antimalarial in Tanzania, it is not surprising that MDR1 N86 was near fixation and the NFD haplotype was very common, occurring in over 50% of samples.

328

Markers of elevated SP resistance are increasing in Tanzania, which has potential impacts on the 329 330 use of SP as a chemopreventive antimalarial. The geographic distribution of the DHPS 581G mutations in Tanzania has historically been limited to Tanga and the Lake districts.^{24,25} We 331 confirm that this remains the case with little evidence of expansion into other regions of 332 Tanzania. The reasons for the lack of spread of this mutation in Tanzania remains unclear and 333 334 warrants further evaluation, especially given the evidence that spread is occurring in the neighboring Democratic Republic of the Congo.²⁶ Previous work has suggested that multiple 335 origins of parasites bearing 581G have occurred in East Africa, suggesting local origins and 336 limited spread.²⁷ However, that work was based on five microsatellites and may not take into 337 338 account the complex stepwise evolutionary history of mutations in DHPS. Importantly, a new focus of the quadruple mutation in DHFR (51I, 59R, 108N, 164L) was identified in Kagera. In 339 340 the laboratory, this form of the enzyme binds pyrimethamine 600 times less tightly than the wild type and about seven times less than the triple mutation (51I, 59R, 108N).²⁸ This results in 341

It is made available under a CC-BY-NC-ND 4.0 International license .

parasites being resistant to therapy *in vitro* at levels higher than what can be reached *in vivo*. The
DHFR/DHPS sextuple mutation (DHFR 51I, 59R, 108N / DHPS 437G, 540E, 581G), has been
associated with the compromise of intermittent preventive treatment in pregnancy (IPTp) and
was found in 11.2% (323/2,894) of samples nationally.²⁹ Given the regional high prevalence of
DHPS 581G and the emergence of DHFR 164L in Northwest Tanzania, additional studies are
warranted to evaluate the benefits of SP based chemoprevention in this region of Tanzania.

348

A major advantage of this study is the large geographic range and large number of samples available for analysis. However, this study design also engenders some limitations. The large number of samples resulted in overall low levels of coverage for the sequencing for most regions (other than the four high priority regions that received extra depth). The samples collected at the three cross-sectional sites performed poorly with our approach, likely due to low parasitemia. The overall coverage in many regions may directly affect the ability to find minority drug resistant variants in the data and we may have filtered out minor variants below 1%.

356

The detection of K13 561H at prevalence above 22% in Karagwe district of Kagera, Tanzania, must raise alarms thatART-R is emerging and that ACTs efficacy is under threat. The independent origin of a new K13 561H extended haplotype raises concern that multiple origins of ART-R mutations will occur in Africa, complicating control. Evolution of partner drug resistance must be monitored carefully and therapeutic efficacy studies are urgently needed to understand the susceptibility of currently circulating K13 mutations in the region.

363 TABLES

Region	DHFR	DHFR	DHFR	DHFR	DHPS	DHPS	DHPS	K13	K13	K13	MDR1	MDR1	MDR1	MDR1	CRT
	N51I	C59R	S108N	I164L	A437G	K540E	A581G	A675V	R561H	R622I	N86F	N86Y	Y184F	D1246Y	K76T
Kagera	0.987	0.913	1.0	0.1521	0.9408	0.9383	0.2593	0.0015	0.077	0.0	0.0	0.0	0.4936	0.0087	0.0164
	(681/690)	(630/690)	(632/632)	(80/526)	(651/692)	(654/697)	(189/729)	(1/680)	(50/649)	(0/709)	(0/223)	(0/223)	(115/233)	(1/115)	(2/122)
Mara	0.988	0.926	0.9947	0.0305	0.9701	0.9724	0.0085	0.0	0.0	0.0	0.0	0.0	0.337	0.0404	0.1395
	(574/581)	(538/581)	(563/566)	(17/558)	(551/568)	(563/579)	(5/590)	(0/585)	(0/535)	(0/578)	(0/75)	(0/75)	(31/92)	(4/99)	(12/86)
Dodoma	0.9787	0.9149	1.0	0.01	0.9509	0.9369	0.0543	0.0	0.0	0.0	0.0	0.0019	0.5204	0.0511	0.0052
	(184/188)	(172/188)	(145/145)	(1/100)	(155/163)	(193/206)	(12/221)	(0/182)	(0/158)	(0/188)	(0/521)	(1/521)	(280/538)	(21/411)	(2/381)
Ruvuma	1.0	0.9846	1.0	0.0	0.9444	0.9275	0.0278	0.0	0.0	0.0	0.0	0.0	0.3623	0.0571	0.0
	(65/65)	(64/65)	(60/60)	(0/46)	(51/54)	(64/69)	(2/72)	(0/68)	(0/38)	(0/68)	(0/60)	(0/60)	(25/69)	(2/35)	(0/50)
Manyara	0.9908	0.9679	1.0	0.011	0.9235	0.9174	0.2273	0.0	0.0056	0.0	0.0	0.0	0.5679	0.0171	0.0078
	(216/218)	(211/218)	(162/162)	(1/91)	(169/183)	(200/218)	(55/242)	0/202)	(1/179)	(0/202)	(0/236)	(0/236)	(138/243)	(2/117)	(1/128)
Songwe	0.9945	0.9613	1.0	0.0044	0.9254	0.9218	0.0201	0.0	0.0	0.0	0.0	0.0	0.4197	0.0034	0.0
	(360/362)	(348/362)	(328/328)	(1/228)	(310/335)	(342/371)	(8/399)	(0/362)	(0/346)	(0/377)	(0/377)	(0/377)	(162/386)	(1/293)	(0/270)
Tanga	1.0	0.9483	1.0	0.0	0.9184	0.8571	0.3846	0.0	0.0	0.0	0.0058	0.0058	0.5141	0.0036	0.035
	(58/58)	(55/58)	(49/49)	(0/48)	(45/49)	(54/63)	(25/65)	(0/56)	(0/30)	(0/45)	(2/342)	(2/342)	(182/354)	(1/277)	(10/286)
Tabora	0.9902	0.943	0.9977	0.016	0.9725	0.975	0.036	0.0022	0.0046	0.0	0.0	0.0047	0.6197	0.0181	0.0331
	(504/509)	(480/509)	(436/437)	(6/376)	(459/472)	(506/519)	(20/555)	(1/464)	(2/438)	(0/498)	(0/213)	(1/213)	(132/213)	(3/166)	(6/181)
Kigoma	1.0	0.9149	1.0	0.0	1.0	1.0	0.3232	0.0	0.0	0.0	0.0	0.0	0.5411	0.0	0.0
	(94/94)	(86/94)	(88/88)	(0/88)	(92/92)	(87/87)	(32/99)	(0/100)	(0/73)	(0/94)	(0/215)	(0/215)	(125/231)	(0/70)	(0/63)
Kilimanjaro	0.9951	0.9557	1.0	0.0	0.9524	0.9608	0.3594	0.0	0.0	0.0	0.0	0.0018	0.637	0.0271	0.0054
	(202/203)	(194/203)	(185/185)	(0/173)	(180/189)	(196/204)	(78/217)	(0/204)	(0/172)	(0/198)	(0/556)	(1/556)	(372/584)	(15/554)	(3/555)
Njombe	0.991	0.9548	1.0	0.0	0.9121	0.8991	0.0474	0.0	0.0036	0.0029	0.0	0.0	0.5754	0.0109	0.0
	(329/332)	(317/332)	(291/291)	(0/246)	(280/307)	(303/337)	(17/359)	(0/331)	(1/279)	(1/345)	(0/238)	(0/238)	(145/252)	(1/92)	(0/97)
Mtwara	0.8602	0.9462	1.0	0.0	0.8025	0.7857	0.0042	0.0	0.0	0.0	0.0014	0.0042	0.4446	0.0295	0.0666
	(160/186)	(176/186)	(107/107)	(0/77)	(126/157)	(165/210)	(1/239)	(0/170)	(0/137)	(0/144)	(1/711)	(3/711)	(325/731)	(18/610)	(39/586)
Dar es	0.9548	0.9266	0.9914	0.0	0.8286	0.8541	0.1198	0.0	0.0	0.0	0.0	0.0	0.5385	0.0	0.0
Salaam	(169/177)	(164/177)	(115/116)	(0/49)	(116/140)	(158/185)	(26/217)	(0/161)	(0/137)	(0/135)	(0/63)	(0/63)	(42/78)	(0/41)	(0/56)
Overall	0.9817	0.9378	0.9984	0.0407	0.9365	0.9306	0.1174	0.0006	0.017	0.0003	0.0008	0.0021	0.518	0.024	0.0262
	(3596/3663)	(3435/3663)	(3161/3166)	(106/2606)	(3185/3401)	(3485/3745)	(470/4004)	(2/3565)	(54/3171)	(1/3581)	(3/3830)	(8/3830)	(2074/4004)	(69/2880)	(75/2861)

Table 1. Prevalence of antimalarial resistance mutations by region. Prevalence reflects the alternate allele.

It is made available under a CC-BY-NC-ND 4.0 International license

It is made available under a CC-BY-NC-ND 4.0 International license .

365 **FIGURES**





Figure 1. Tanzania malaria prevalence and study design. Panel A depicts a map of Tanzania

showing malaria prevalence in children aged 0-59 months in 2017 as a color gradient (National

369 Malaria Control Program data). Health facilities where sampling occurred for this study are

shown as green dots, while community cross sectional collection sites are shown as yellow

371 squares. Panel B shows the study design flowchart showing the number of samples collected at

health facilities and cross sectional surveys and the success of genotyping. Priority for

373 genotyping and analysis was given to regions in the northwest.

It is made available under a CC-BY-NC-ND 4.0 International license .

375



376

377 Figure 2. Antimalarial resistance polymorphisms in Tanzania. Panels A and B show K13 561H mutations in Tanzania by region (A) and by district in Kagera (B). In Panel A, white areas 378 represent no sampling, gray areas represent sampled areas where no K13 561H was found, and 379 colored areas are shaded by the frequency of samples with the 56H mutation. The red box 380 surrounds the area plotted in Panel B, which is a map of Kagera showing K13 561H prevalence 381 in each district sampled. DHFR 164L (Panel C) and DHPS 581G (Panel D) prevalence in 382 383 sampled regions are shown in color gradients. Regions with no sampling are shown in white and regions where a polymorphism was not detected is shown in grey. 384

It is made available under a CC-BY-NC-ND 4.0 International license .

386



387



are shown in maroon. Rwandan isolates are in the blue box, while Tanzanian isolates are shown

in the red boxes. Grey regions represent loci where a call could not be made.

It is made available under a CC-BY-NC-ND 4.0 International license .





Figure 4. Extended Haplotype Heterozygosity (EHH) analysis of 561H haplotypes. Panel A

shows the extended haplotype for the RW/TZ1 561H haplotype (red-derived) compared to

wildtype parasites (blue-ancestral). Panel B shows the extended haplotype of the TZ2 561Hhaplotype.

It is made available under a CC-BY-NC-ND 4.0 International license .

398 Authors contribution

399 DSI, JJJ and JB formulated the original idea. DSI, CIM, RAM, MDS and CB conducted the field

400 surveys. DG, AF, AS, BL, ZPH, KN and AL performed data analysis under the guidance of

401 DSI, JJJ and JB. JJJ, AS, AF, DG, BL, ZPH, CB, DP, MDS, JB, and DSI wrote and edited the

402 manuscript. All authors contributed to the article and approved the submitted version.

403 Acknowledgements:

404 The authors wish to thank participants and parents/guardians of all children who took part in the

surveillance. We acknowledge the contribution of the following project staff and other

406 colleagues who participated in data collection and/or laboratory processing of samples; Raymond

407 Kitengeso, Ezekiel Malecela, Muhidin Kassim, Athanas Mhina, August Nyaki, Juma Tupa,

408 Anangisye Malabeja, Emmanuel Kessy, George Gesase, Tumaini Kamna, Grace Kanyankole,

409 Oswald Osca, Richard Makono, Ildephonce Mathias, Godbless Msaki, Rashid Mtumba, Gasper

410 Lugela, Gineson Nkya, Daniel Chale, Richard Malisa, Sawaya Msangi, Ally Idrisa, Francis

411 Chambo, Kusa Mchaina, Raymond Kitengeso, Neema Barua, Christian Msokame, Rogers

412 Msangi, Salome Simba, Hatibu Athumani, Mwanaidi Mtui, Rehema Mtibusa, Jumaa Akida,

413 Ambele Yatinga, Tilaus Gustav, Oksana Kharabora and Claudia Gaither. The finance,

414 administrative and logistic support team at NIMR: Christopher Masaka, Millen Meena, Beatrice

415 Mwampeta, Gracia Sanga, Neema Manumbu, Halfan Mwanga, Arison Ekoni, Twalipo Mponzi,

416 Pendael Nasary, Denis Byakuzana, Alfred Sezary, Emmanuel Mnzava, John Samwel, Daud

417 Mjema, Seth Nguhu, Thomas Semdoe, Sadiki Yusuph, Alex Mwakibinga, Rodrick Ulomi and

418 Andrea Kimboi. Management of the National Institute for Medical Research, National Malaria

419 Control Program and President's Office-Regional Administration and Local Government

420 (Regional administrative secretaries of the 13 regions, and district officials, staff from all 100

421 HFs and Community Health Workers from the 3 community cross sectional regions. Technical

422 and logistics support from the Bill and Melinda Gates Foundation team is highly

423 appreciated. Permission to publish the manuscript was sought and obtained from the Director

424 General of NIMR.

425 Funding

It is made available under a CC-BY-NC-ND 4.0 International license .

- 426 This work was supported, in whole, by the Bill & Melinda Gates Foundation [grant number
- 427 002202]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0
- 428 Generic License has already been assigned to the Author Accepted Manuscript version that
- 429 might arise from this submission. This study was also funded by the National Institute for
- Allergy and Infectious Diseases (R01AI156267 to JAB, DSI and JJJ; K24AI134990 to JJJ).
- 431 **Data Availability**: All sequencing data has been submitted to SRA (# pending). Other metadata
- 432 is available from the corresponding author upon reasonable request. Code for analysis is
- 433 available at: https://github.com/bailey-lab/MSMT_2021_DR_analyses.

It is made available under a CC-BY-NC-ND 4.0 International license .

434 **REFERENCES**

435	1	World Health Organization. World malaria report 2022. World Health Organization, 2022.
436 437	2	Trape JF. The public health impact of chloroquine resistance in Africa. <i>Am J Trop Med Hyg</i> 2001; 64 : 12–7.
438 439 440	3	Spring MD, Lin JT, Manning JE, <i>et al.</i> Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. <i>Lancet Infect Dis</i> 2015; 15 : 683–91.
441 442 443	4	Programme GM. Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010-2019). 2020; published online Nov 19. https://www.who.int/publications/i/item/9789240012813 (accessed Oct 30, 2023).
444 445	5	Ward KE, Fidock DA, Bridgford JL. Plasmodium falciparum resistance to artemisinin- based combination therapies. <i>Curr Opin Microbiol</i> 2022; 69 : 102193.
446 447	6	Conrad MD, Asua V, Garg S, <i>et al.</i> Evolution of Partial Resistance to Artemisinins in Malaria Parasites in Uganda. <i>N Engl J Med</i> 2023; 389 : 722–32.
448 449	7	Mihreteab S, Platon L, Berhane A, <i>et al.</i> Increasing Prevalence of Artemisinin-Resistant HRP2-Negative Malaria in Eritrea. <i>N Engl J Med</i> 2023; 389 : 1191–202.
450 451	8	Fola AA, Feleke SM, Mohammed H, <i>et al.</i> Plasmodium falciparum resistant to artemisinin and diagnostics have emerged in Ethiopia. <i>Nat Microbiol</i> 2023; 8 : 1911–9.
452 453 454 455	9	Moser KA, Madebe RA, Aydemir O, <i>et al.</i> Describing the current status of Plasmodium falciparum population structure and drug resistance within mainland Tanzania using molecular inversion probes. <i>Mol Ecol</i> 2020; published online Oct 26. DOI:10.1111/mec.15706.
456 457 458	10	Uwimana A, Legrand E, Stokes BH, <i>et al.</i> Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. <i>Nat Med</i> 2020; published online Aug 3. DOI:10.1038/s41591-020-1005-2.
459 460 461	11	Bayih AG, Getnet G, Alemu A, Getie S, Mohon AN, Pillai DR. A Unique Plasmodium falciparum K13 Gene Mutation in Northwest Ethiopia. <i>Am J Trop Med Hyg</i> 2016; 94 : 132–5.
462 463 464	12	Kirby R, Giesbrecht D, Karema C, <i>et al.</i> Examining the Early Distribution of the Artemisinin-Resistant Plasmodium falciparum kelch13 R561H Mutation in Areas of Higher Transmission in Rwanda. <i>Open Forum Infect Dis</i> 2023; 10 : ofad149.
465 466 467	13	Uwimana A, Umulisa N, Venkatesan M, <i>et al.</i> Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. <i>Lancet Infect Dis</i> 2021; 21 : 1120–8.

It is made available under a CC-BY-NC-ND 4.0 International license .

468 469 470	14	WHO Status report on artemisinin and ACT resistance (April 2017). World Health Organization, 2017 https://www.who.int/malaria/publications/atoz/artemisinin-resistance- april2017/en/ (accessed Feb 3, 2020).
471 472	15	Verity R, Aydemir O, Brazeau NF, <i>et al.</i> The impact of antimalarial resistance on the genetic structure of Plasmodium falciparum in the DRC. <i>Nat Commun</i> 2020; 11 : 2107.
473 474 475	16	Rogier E, Battle N, Bakari C, <i>et al.</i> Plasmodium falciparum pfhrp2 and pfhrp3 gene deletions among patients enrolled at 100 health facilities throughout Tanzania: February to July 2021. bioRxiv. 2023; published online Aug 5. DOI:10.1101/2023.07.29.23293322.
476 477 478 479	17	Bwire GM, Ngasala B, Mikomangwa WP, Kilonzi M, Kamuhabwa AAR. Detection of mutations associated with artemisinin resistance at k13-propeller gene and a near complete return of chloroquine susceptible falciparum malaria in Southeast of Tanzania. <i>Sci Rep</i> 2020; 10 : 1–7.
480 481 482 483 484	18	Ishengoma DS, Mmbando BP, Mandara CI, <i>et al.</i> Trends of Plasmodium falciparum prevalence in two communities of Muheza district North-eastern Tanzania: correlation between parasite prevalence, malaria interventions and rainfall in the context of re- emergence of malaria after two decades of progressively declining transmission. <i>Malar J</i> 2018; 17 : 252.
485 486 487	19	Oyola SO, Ariani CV, Hamilton WL, <i>et al.</i> Whole genome sequencing of Plasmodium falciparum from dried blood spots using selective whole genome amplification. <i>Malar J</i> 2016; 15 . DOI:10.1186/s12936-016-1641-7.
488 489	20	Niaré K, Greenhouse B, Bailey JA. An optimized GATK4 pipeline for Plasmodium falciparum whole genome sequencing variant calling and analysis. <i>Malar J</i> 2023; 22 : 207.
490 491	21	Blasco B, Leroy D, Fidock DA. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. <i>Nat Med</i> 2017; 23 : 917–28.
492 493 494	22	Takala-Harrison S, Jacob CG, Arze C, <i>et al.</i> Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. <i>J Infect Dis</i> 2015; 211 : 670–9.
495 496 497	23	Katalyeba PO. Rural - Rural Movements in East Africa: a Study of Rwandan and Southern Ugandans in Karagwe District, Tanzania. 2002. http://researcharchive.vuw.ac.nz/handle/10063/461 (accessed Oct 28, 2023).
498 499 500	24	Gesase S, Gosling RD, Hashim R, <i>et al.</i> High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. <i>PLoS One</i> 2009; 4 : e4569.
501 502 503	25	Ngondi JM, Ishengoma DS, Doctor SM, <i>et al.</i> Surveillance for sulfadoxine-pyrimethamine resistant malaria parasites in the Lake and Southern Zones, Tanzania, using pooling and next-generation sequencing. <i>Malar J</i> 2017; 16 : 236.

It is made available under a CC-BY-NC-ND 4.0 International license .

- Deutsch-Feldman M, Aydemir O, Carrel M, *et al.* The changing landscape of Plasmodium
 falciparum drug resistance in the Democratic Republic of Congo. *BMC Infect Dis* 2019; 19:
 872.
- Taylor SM, Antonia AL, Harrington WE, *et al.* Independent lineages of highly sulfadoxine resistant Plasmodium falciparum haplotypes, eastern Africa. *Emerg Infect Dis* 2014; 20:
 1140–8.
- Hyde JE. Antifolate resistance in Africa and the 164-dollar question. *Trans R Soc Trop Med Hyg* 2008; **102**. DOI:10.1016/j.trstmh.2008.01.003.
- 512 29 Chico RM, Cano J, Ariti C, *et al.* Influence of malaria transmission intensity and the 581G
 513 mutation on the efficacy of intermittent preventive treatment in pregnancy: systematic
 514 review and meta-analysis. *Trop Med Int Health* 2015; **20**: 1621–33.